Barcelona, Spain
Barcelona, Spain
SEARCH FILTERS
Time filter
Source Type

The present invention relates to methods and compositions for the treatment or prevention of diseases and disorder associated with myeloproliferative and lymphoproliferative disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing diseases and disorder associated with myeloproliferative and lymphoproliferative disorders.


Patent
Oryzon Genomics | Date: 2017-02-22

The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, -CH_(2)C(=O)NH_(2), heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is -NH-; (L) is chosen from a single bond, -CH_(2)-, -CH_(2)CH_(2)-, -CH_(2)CH_(2)CH_(2)-, and -CH_(2)CH_(2)CH_(2)CH_(2)-; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from - NH_(2), -NH(C_(1)-C_(6) alkyl), -N(C_(1)-C_(6) alkyl)(C_(1)-C_(6) alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. The compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer.


Patent
Oryzon Genomics | Date: 2014-02-20

The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.


Patent
Oryzon Genomics | Date: 2016-09-01

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.


Patent
Oryzon Genomics | Date: 2016-09-21

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.


The invention relates to methods and compositions for the treatment or prevention of protein conformation disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing a protein conformation disorder, such as, e.g., Huntington Disease.


The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).


Patent
Oryzon Genomics | Date: 2014-03-27

The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, CH_(2)C(=0)NH_(2), heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is NH; (L) is chosen from a single bond, CH_(2), CH_(2)CH_(2), CH_(2)CH_(2)CH_(2), and CH_(2)CH_(2)CH_(2)CH_(2); and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from NH_(2), NH(C_(1)-C_(6 )alkyl), N(C_(1)-C_(6 )alkyl)(C_(1)-C_(6 )alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. (A)X(A)(B)(Z)-(L)-(D) formula (I) The compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer.


Patent
Oryzon Genomics | Date: 2015-02-20

The present invention relates to phenylcyclopropylamine derivatives. In particular, pharmaceutical compositions comprising phenylcyclopropylamine derivatives are provided. The compounds of this invention can, inter alia, be used for the treatment and the prevention of cancer as well as neurodegenerative diseases or disorders.


Patent
Oryzon Genomics | Date: 2015-05-13

The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer.

Loading Oryzon Genomics collaborators
Loading Oryzon Genomics collaborators